<DOC>
	<DOCNO>NCT02183233</DOCNO>
	<brief_summary>The aim trial ass efficacy safety Eschscholtzia Californica ( EC ) treat patient psycho-physiologic insomnia double-blind randomise placebo control trial 28-day treatment duration .</brief_summary>
	<brief_title>Efficacy Safety Eschscholtzia Californica Treating Primary Insomnia</brief_title>
	<detailed_description />
	<mesh_term>Sleep Initiation Maintenance Disorders</mesh_term>
	<criteria>Male female 18 65 year old Diagnosis psychophysiologic insomnia , accord criterion DSMIV ( Diagnostic Statistical manual Version IV ) Written informed consent Patient already take investigational drug take part another trial past three month Patient history psychiatric disease , : anxiety disorder ; score HAMA ( Hamilton anxiety scale ) must &lt; 10 depression accord DSM IV criterion ; score HAMD ( Hamilton depression scale ) must &lt; 10 mania schizophrenia dementia Patient history neurologic disease , : Parkinson syndrome crania cerebral trauma post syndrome brain tumor fibromyalgia Patient history iatrogenic insomnia , due drug like antidepressor , neuroleptic benzodiazepine , hypnotic Patient hypersomnia sleep apnea syndrome Patient pathology induce chronic pain , pyrosis , nocturnal pollakiuria , dyspnea Patient Restless Leg Syndrome Patient severe hepatic renal insufficiency judge regard clinically relevant investigator , know clinically significant disease may induce risk patient participate trial Breast feeding pregnant female , female efficient contraception method Patient nonstabilised thyroid dysfunction Patient know allergy Eschscholtzia Californica compound Patient alcohol drug dependency Patient drinking tea , coffee CocaCola 4 p.m .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>